Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00073593
Status:
COMPLETED
Last Update Posted:
2011-11-10
First Post:
2003-11-26
Brief Title:
Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
Sponsor:
The Medicines Company
Organization:
The Medicines Company
Study Overview
Official Title:
A Study Comparing Angiomax Bivalirudin to Heparin With Protamine Reversal in Patients Undergoing Coronary Artery Bypass OPCAB Surgery
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPCAB
Brief Summary:
The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EVOLUTION | None | None | None |